Pressmeddelande

BioStock: CombiGene positive to new license agreement for CG01

Cision Publicerad: 26 Jun 12:43

CombiGene has entered into a new license agreement with Spark Therapeutics regarding intellectual property related to the epilepsy project, CG01. CombiGene’s CEO Peter Ekolind believes that they are now in better position to find a new development partner who can take the epilepsy treatment all the way to patients and the market.
– We are looking for a partner who can pick up where Spark left off, and with the agreement in place, we can use the data generated over the past two years in our search, says Peter Ekolind.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/06/combigene-positive-to-new-license-agreement-for-cg01/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om CombiGene

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!